Nicotine-Qß Vaccine

Smoking cigarettes and related tobacco dependence is one of the leading causes of preventable physical disabilities and deaths worldwide, and nicotine is the dominant substance responsible for addiction to tobacco. Thus, in recent years, many researchers have focused on finding a vaccine against nicotine.

Immunization – a novel approach against nicotine addiction

A novel approach has been adopted for immunization against nicotine, in which the vaccinated individual generates special antibodies, which are directed against free nicotine in the blood.

However, nicotine is a small non-immunogenic molecule. But when nicotine is conjugated to an immunogenic protein and presented to the human immune system it induces antibodies, which are directed against nicotine.

These antibodies bind nicotine and thereby prevent its passage through the blood-brain barrier. As a consequence, nicotine does not reinforce the nicotine addiction in the brain and the vaccinated person has no reward effect after smoking, thus breaking the vicious circle of nicotine addiction.

In this way, a new vaccine was developed based on a virus-like particle (VLP)-nicotine conjugate, which in fact provokes the expected antibody responses.

CRS performed a FiH clinical trial with the first Nicotine-Qß vaccine

CRS performed the first in human (FiH) clinical trial to investigate the safety and tolerability of different doses of a Nicotine-Qß vaccine in healthy volunteers.

The results clearly confirm immunotherapy as a novel and feasible approach for the treatment of nicotine addiction.



CRO Leadership Awards 2019

CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability.

European Biotechnology Guide

Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019.

EcoVadis – CSR Rating

Based on the CSR rating by EcoVadis in 2022 CRS has been granted Silver Recognition Level.